Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Go back to Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis| ALKERMES (NASDAQ: ALKS) | Delayed: 52.58 -0.27 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.85 | 52 Week High | $80.71 | |||
| Open | $52.55 | 52 Week Low | $27.14 | |||
| Day High | $53.27 | P/E | 404.46 | |||
| Day Low | $52.35 | EPS | $0.13 | |||
| Volume | 1,837,064 | |||||
